Leerink Partnrs Equities Analysts Raise Earnings Estimates for Cullinan Oncology, Inc. (NASDAQ:CGEM)

Cullinan Oncology, Inc. (NASDAQ:CGEMFree Report) – Equities researchers at Leerink Partnrs increased their FY2024 earnings per share estimates for shares of Cullinan Oncology in a report released on Monday, February 5th. Leerink Partnrs analyst A. Berens now expects that the company will earn ($4.06) per share for the year, up from their previous forecast of ($4.39). The consensus estimate for Cullinan Oncology’s current full-year earnings is ($4.10) per share. Leerink Partnrs also issued estimates for Cullinan Oncology’s FY2025 earnings at ($4.18) EPS and FY2026 earnings at ($2.91) EPS.

Cullinan Oncology Stock Performance

NASDAQ CGEM opened at $18.70 on Thursday. The business has a fifty day moving average price of $11.42 and a 200 day moving average price of $10.24. Cullinan Oncology has a one year low of $7.64 and a one year high of $19.11. The company has a market cap of $800.00 million, a P/E ratio of -5.00 and a beta of 0.24.

Cullinan Oncology (NASDAQ:CGEMGet Free Report) last posted its quarterly earnings data on Wednesday, November 8th. The company reported ($0.91) EPS for the quarter, meeting the consensus estimate of ($0.91).

Insider Activity at Cullinan Oncology

In related news, insider Corrine Savill sold 18,684 shares of the stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $12.14, for a total value of $226,823.76. Following the completion of the transaction, the insider now directly owns 165,990 shares of the company’s stock, valued at approximately $2,015,118.60. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Cullinan Oncology news, insider Corrine Savill sold 18,684 shares of the company’s stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $12.14, for a total value of $226,823.76. Following the completion of the sale, the insider now directly owns 165,990 shares in the company, valued at approximately $2,015,118.60. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Nadim Ahmed sold 4,272 shares of the company’s stock in a transaction on Tuesday, December 26th. The shares were sold at an average price of $9.24, for a total value of $39,473.28. Following the completion of the sale, the chief executive officer now owns 111,550 shares of the company’s stock, valued at $1,030,722. The disclosure for this sale can be found here. In the last ninety days, insiders sold 110,514 shares of company stock valued at $1,539,055. 8.82% of the stock is owned by insiders.

Institutional Trading of Cullinan Oncology

Several large investors have recently added to or reduced their stakes in CGEM. Swiss National Bank grew its holdings in Cullinan Oncology by 8.1% in the 1st quarter. Swiss National Bank now owns 36,200 shares of the company’s stock valued at $379,000 after buying an additional 2,700 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Cullinan Oncology by 20.5% during the 1st quarter. JPMorgan Chase & Co. now owns 24,172 shares of the company’s stock worth $253,000 after purchasing an additional 4,115 shares during the period. MetLife Investment Management LLC grew its holdings in shares of Cullinan Oncology by 57.0% during the 1st quarter. MetLife Investment Management LLC now owns 15,398 shares of the company’s stock worth $161,000 after purchasing an additional 5,590 shares during the period. Rhumbline Advisers grew its holdings in shares of Cullinan Oncology by 4.7% during the 1st quarter. Rhumbline Advisers now owns 32,045 shares of the company’s stock worth $336,000 after purchasing an additional 1,445 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Cullinan Oncology by 2.3% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 178,150 shares of the company’s stock worth $1,866,000 after purchasing an additional 3,937 shares during the period. 86.31% of the stock is currently owned by hedge funds and other institutional investors.

Cullinan Oncology Company Profile

(Get Free Report)

Cullinan Oncology, Inc a clinical-stage biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally bioavailable small-molecule that is in a Phase IIb dose escalation for treating patients with non-small cell lung cancer.

Featured Articles

Earnings History and Estimates for Cullinan Oncology (NASDAQ:CGEM)

Receive News & Ratings for Cullinan Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Oncology and related companies with MarketBeat.com's FREE daily email newsletter.